Quality-Adjusted Life Years Accrued with Cabozantinib in Patients with Advanced Hepatocellular Carcinoma (AHCC) in the CELESTiAL Trial

被引：0

作者：

Venerito, Marino ^{[1
]}

Abou-Alfa, G. K. ^{[2
]}

Mollon, P. ^{[3
]}

Meyer, T. ^{[4
]}

Cheng, A. -L ^{[5
]}

El-Khoueiry, A. B. ^{[6
]}

Kelley, R. K. ^{[7
]}

Baron, A. D. ^{[8
]}

Benzaghou, F. ^{[9
]}

Valcheva, V. ^{[3
]}

Hazra, S. ^{[10
]}

Mangeshkar, M. ^{[10
]}

Freemantle, N. ^{[4
]}

机构：

[1] Univ Klinikum Magdeburg, Magdeburg, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Ipsen Pharma SAS, Boulogne, France

[4] UCL, London, England

[5] Staatliche Univ Taiwan, Taipei, Taiwan

[6] Norris Comprehens Canc Ctr, Los Angeles, CA USA

[7] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[8] Calif Pacific Med Ctr, San Francisco, CA USA

[9] Ipsen Innovat, Les Ulis, France

[10] Exelixis Inc, San Francisco, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

174

引用

页码：61 / 61

页数：1